Evolus

EOLS

Biotech

Health Care

Pharma

Country

US

Industry

Health Care

Market Cap

Small Cap

Num. Employees

224

IPO Date

Feb 8, 2018

Create Alert

EOLS

Country

US

Industry

Health Care

Biotech

Health Care

+1

Create Alert

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 224 full-time employees. The company went IPO on 2018-02-08. Its first commercial product is Jeuveau, which is a 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. Jeuveau is manufactured using Hi-Pure technology. The firm commercially launched Jeuveau in the United States. The firm manufactures both Jeuveau and BOTOX. BOTOX (onabotulinumtoxinA) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.